CDTX Cidara Therapeutics Inc.

3.47
-0.06  -2%
Previous Close 3.53
Open 3.5
Price To Book 2.35
Market Cap 114,649,824
Shares 33,040,295
Volume 268,840
Short Ratio
Av. Daily Volume 310,764
Stock charts supplied by TradingView

NewsSee all news

  1. Cidara Therapeutics Announces Commencement of Rights Offering

    SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the

  2. Cidara Therapeutics Announces Proposed Rights Offering

    Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Cidara

  3. Cidara Therapeutics to Present at Two Upcoming Medical Conferences

    SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at

  4. Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top

  5. Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due mid-2020.
Rezafungin (CD101) ReSTORE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 3 trial pending funding.
Rezafungin (CD101) ReSPECT
Prophylaxis
Phase 2 data released July 29, 2019 - noted all objectives met.
Rezafungin (CD101) STRIVE B
Candidemia

Latest News

  1. Cidara Therapeutics Announces Commencement of Rights Offering

    SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the

  2. Cidara Therapeutics Announces Proposed Rights Offering

    Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Cidara

  3. Cidara Therapeutics to Present at Two Upcoming Medical Conferences

    SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at

  4. Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top

  5. Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three

  6. Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion

  7. Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

    SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three

  8. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  9. Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief

  10. Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDTX, CGC, GNRC, LOW, and MDCO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  11. Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

    Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize